Expanding Business into Biopharmaceuticals and Related Sectors

FarmGen Science announced on June 9 that it has signed a memorandum of understanding (MOU) with TS Bio to expand its business into the regenerative medicine and biopharmaceutical sectors.


Pharmgen Science headquarters located in Bangbae-dong, Seocho-gu, Seoul. Pharmgen Science

Pharmgen Science headquarters located in Bangbae-dong, Seocho-gu, Seoul. Pharmgen Science

View original image

This agreement is part of a strategic collaboration aimed at expanding FarmGen Science’s business scope into regenerative medicine and biopharmaceuticals, and securing new growth engines, based on the company’s capabilities in pharmaceutical development, regulatory approval, and commercialization.


Established in 2017, TS Bio is a biotechnology company specializing in the research and development of cell and gene therapies, leveraging regenerative medicine technologies based on immune cell and stem cell platforms. The company operates cell storage services and regenerative medicine businesses utilizing certified Good Manufacturing Practice (GMP) facilities, thereby strengthening its technological expertise and operational capabilities in related fields.


The two companies plan to cooperate across a range of areas, including sharing information related to clinical pipelines in regenerative medicine and biopharmaceuticals, collaborating on applied research, reviewing the feasibility of new drug development and clinical application, working together on commercialization, manufacturing, and distribution, and establishing joint business and marketing strategies.


FarmGen Science intends to take a leading role in enhancing the practical commercialization potential of development achievements by leveraging its accumulated experience in regulatory approval and commercialization, as well as its specialized workforce. Through these efforts, the company aims to strengthen its competitiveness in the fields of regenerative medicine and biopharmaceuticals.


A representative from FarmGen Science stated, “This agreement marks an important milestone in our company’s mid-to-long-term growth strategy. By expanding into regenerative medicine and biopharmaceuticals, we will create new business opportunities and strive to achieve tangible results.”



Meanwhile, FarmGen Science continues to expand its new pipeline to strengthen its research and development capabilities. Major pipelines include a liver-specific MRI contrast agent (RD1303), a treatment for reflux esophagitis (RD1305), an anti-obesity drug (RD5306), a treatment for autoimmune diseases (RD5308), an oral anti-obesity drug (RD5309), a dual-action oral anti-obesity drug (RD5310), and a treatment for liver fibrosis (RD5311).


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing